|
Without TXA |
With TXA |
Number (n) |
25 |
81 |
Gender (proportion of female %) |
60 |
57 |
Age (years) |
73 ± 10 |
67 ± 12 |
Comorbidities |
|
|
Body mass index (kg/m2) |
26 ± 4 |
27 ± 5 |
Median ASA score (Q1;Q3) |
3 (3;3) |
2 (2;2) |
Cardio-vascular history (%) |
80 |
14 |
Antiplatelet agents at D-30 (%) |
44 |
20 |
Anticoagulant agents D-30 (%) |
28 |
2 |
Hb D-1 (g/dL) |
13.3 ± 1.1 |
13.4 ± 1.1 |
Type of surgery |
|
|
THR (%) |
60 |
50 |
TKR (%) |
32 |
29 |
RTHR (%) |
8 |
21 |
Perioperative period |
|
|
Tranexamic acid |
|
|
Intraoperative dose (mg/kg) |
0 |
17 ± 15 |
Dose per 24h (mg/kg/24h) |
0 |
75 ± 25 |
Fluids (intraoperative and RR, in mL) |
2140 ± 700 |
2080 ± 764 |
Postoperative intravenous iron (%) |
80 |
87 |
Transfusion |
|
|
Allogeneic transfusion (between D0 et D+5, in %) |
40 |
11 |
Number of transfused patients (n) |
10 |
9 |
THR (%) |
40 |
5 |
TKR (%) |
25 |
5 |
RTHR (%) |
100 |
38 |
Median number of RBC unit (Q1,Q3) |
2 (2;3) |
2 (2;2) |
Mean Hb transfusional threshold (g/dL) |
8.4 ± 1,3 |
9.1 ± 0,6 |
TXA: Tranexamic Acid; ASA: American Society of Anesthesiology; Hb: Hemoglobin;
THR: Total Hip Replacement; TKR: Total Knee Replacement; RTHR: Revision
Total Hip Replacement; RBC: Red Blood Cell